Products Backed by Science
We’ve developed scientific rigor from our experience at leading companies such as Johnson & Johnson and GlaxoSmithKline. This background is what gives us such high standards. Our team of scientists and medical advisors continue to push for the evolution of standards for CBD and supplements. Our manufacturing sites can prove they are high quality through GMP-certification and FDA inspections. It is mission critical for us to develop products we can stand behind.
Driven by Inspiration
Millions of people worldwide look to CBD to help manage their pain or stress. CBD has been shown to support mental focus during the day, support healthy stress levels, and even support rest and relaxation for sleep. It’s become our mission to bring better CBD to the world, with only high-quality products that we can stand behind.
NextEvo CBD is better because our SmartSorb™ technology optimizes CBD for better bioavailability, so your body can absorb more of it. CBD is oil-soluble, which means it’s hard for the human body to absorb.
While other CBD products can pass right through your system with little absorption, we’ve created a technology that allows your body to soak up the CBD goodness.
Technology that’s Clinically Proven
We discovered the best formulation for absorption, and we call it Smartsorb™. SmartSorb™ technology works by combining the elements of extraction, emulsion and formulation in a way that’s clinically proven to optimize absorption. In fact, it absorbs 4x better than oil-based formulations, and works faster too.
From Inspiration to Science to Technological Discovery - we bring you NextEvo.
Our Leadership Team
John is a seasoned consumer packaged goods industry veteran with 25 years of experience in the sector.
John has served as a marketing and sales leader for Johnson & Johnson as well as McNeil Consumer & Specialty Pharmaceuticals, the makers of Tylenol, and Lifescan on the OneTouch Glucose Monitor brand, and has a deep-seated understanding of creating value and changing the perspective of consumers from these roles.
John received both his B.S. in Accountancy and studied for his M.B.A. at Villanova University.
Gerry McNally is a seasoned consumer healthcare R&D executive who has a track record of leading the conception, development, and commercialization of new products in dynamic market-driven environments.
Gerry's creative talent, OTC industry knowledge, and consumer understanding have been key to his success in bringing new products and technologies to the consumer healthcare market. His background in the regulated pharmaceutical industry combined with his experience in consumer healthcare and patient-centric drug development provides a unique perspective. With more than 25 years of experience as an R&D leader in the consumer healthcare industry, Gerry is acutely aware of the roles that leadership and the R&D function have in driving innovation and growth.
During his tenure at McNeil Consumer Healthcare and Johnson & Johnson, Gerry was instrumental in leading the development of numerous innovative and highly successful products and launching multiple novel drug delivery technologies.
Innovations that have made a real difference for patients and consumers include various taste-masking technologies for pediatric and adult products, unique formulations for combination products such as Imodium® Multi-Symptom Relief, and Pepcid® Complete and novel formats such as
Tylenol® Rapid Release Gels that have stood the test of time in the marketplace.
Gerry’s career history also includes having a leadership role in several very successful Rx to OTC switches such as Pepcid® AC and Zyrtec®.
His diverse industry experience includes areas such as specialty chemicals, large OTC joint venture partnerships, specialty pharmaceuticals, OTC, and nutritional products which give him a broad perspective on technology in the consumer healthcare industry.
Gerry earned his Ph.D. and BSc Hons. in Chemistry from University College Dublin, Ireland. He holds over 30 patents in the field of drug delivery/pharmaceutical formulation, has authored several papers, and
delivered presentations at industry conferences.
David is a molecular diagnostics and biopharmaceutical industry veteran with over 25 years of global experience.
As Chief Medical Officer for multiple companies including Adamas, Aquinox, Crescendo Bioscience, Schiff Nutrition, and SetPoint Medical, David has played pivotal roles in moving early-stage R&D programs successfully through clinical development and product commercialization and evaluating a broad range of in-licensing opportunities. He has a keen interest in anti-inflammatory science.
David is a graduate of Yale University as well as the New York University Grossman School of Medicine.